Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis

Stepan, Jan J.<sup>1</sup>; Burr, David B.<sup>2</sup>; Pavo, Imre<sup>3</sup>; Sipos, Adrien<sup>4</sup>; Michalska, Dana<sup>5</sup>; Li, Jiliang<sup>2</sup>; Fahrleitner-Pammer, Astrid<sup>6</sup>; Petto, Helmut<sup>3</sup>; Westmore, Michael<sup>4</sup>; Michalsky, David<sup>7</sup>; Sato, Masahiko<sup>4</sup>; Dobnig, Harald<sup>6</sup>

Affiliations

¹Institute of Rheumatology, Charles University, Faculty of Medicine, Prague, Czech Republic

²Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA

³Area Medical Center Vienna, Eli Lilly and Company, Vienna, Austria

⁴Lilly Research Laboratories, Indianapolis, IN, USA

⁵Department of Internal Medicine 3, Charles University, Faculty of Medicine Prague, Czech Republic

⁶Department of Internal Medicine, Medical University Graz, Austria

⁷Department of Surgery, Charles University, Faculty of Medicine Prague, Czech Republic

Abstract and keywords

Marked suppression of bone turnover by bisphosphonates is associated with increased bone microdamage accumulation in animal models. The purpose of this study was to test the hypothesis that long-term treatment with alendronate (ALN) results in accumulation of microdamage in bone in women after menopause. Sixty-six postmenopausal women with osteoporosis (mean age of 68.0 years and mean BMD T-score of − 1.7 at total hip and − 2.8 at lumbar spine; 62% with prevalent fractures) were evaluated in this cross-sectional analysis. Thirty-eight had been treated previously with ALN (10 mg/day or 70 mg/week for a mean duration of 63.6 months) while twenty-eight were treatment naive (TN). Without adjustments, crack surface density (Cr.S.Dn) and crack density (Cr.Dn) were not different between ALN and TN patients. After adjustment for potential confounders (age, prevalent fractures, femoral neck BMD, activation frequency and center), Cr.Dn was elevated in ALN patients (P = 0.028 and P = 0.069 for Cr.S.Dn). In ALN patients only, lower femoral neck BMD (Cr.S.Dn, r = − 0.58, P = 0.003; Cr.Dn, r = − 0.54, P = 0.005) and increased age (Cr.S.Dn, r = 0.43, P = 0.03; Cr.Dn, r = 0.43, P = 0.03) were associated with microdamage accumulation. Among potential confounders, femoral neck BMD was the only independent predictor for these correlations (P = 0.04 for Cr.Dn and P = 0.03 for Cr.S.Dn). We conclude that increased microdamage accumulation may occur in low BMD patients treated with alendronate.

Keywords: Osteoporosis; Histomorphometry; Microdamage; Bone mineral density; Alendronate

Links

DOI: 10.1016/j.bone.2007.04.198

PubMed: 17597017

WoS: 000248898600011

History

Received: 2007-01-18

Revised: 2007-04-27

Accepted: 2007-04-27

Online: 2007-05-18

Cited Works (22)

Year	Entry
2000	Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. November 2000;27(5):687-694.
1995	Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB; Group, Alendronate Phase III Osteoporosis Treatment Study. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. NEJM. November 30, 1995;333(22):1437-1443.
2006	Allen MR, Iwata K, Phipps R, Burr DB. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone. October 2006;39(4):872-879.
1997	Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. September 15, 1997;100(6):1475-1480.
1998	Zioupos P, Currey JD. Changes in the stiffness, strength, and toughness of human cortical bone with age. Bone. January 1998;22(1):57-66.
2004	Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. NEJM. March 18, 2004;350(12):1189-1199.
1999	Huja SS, Hasan MS, Pidaparti R, Turner CH, Garetto LP, Burr DB. Development of a fluorescent light technique for evaluating microdamage in bone subjected to fatigue loading. J Biomech. November 1999;32(11):1243-1249.
1997	Mori S, Harruff R, Ambrosius W, Burr DB. Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone. December 1997;21(6):521-526.
1993	Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palmero L, Scott J, Vogt TM; Study of Osteoporotic Fractures Research Group. Bone density at various sites for prediction of hip fractures. Lancet. January 9, 1993;341(8837):72-75.
1998	Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ; Fracture Intervention Trial Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. December 23, 1998;280(24):2077-2082.
2000	Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. April 2000;15(4):613-620.
2001	Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. May 2001;28(5):524-531.
1995	Schaffler MB, Choi K, Milgrom C. Aging and matrix microdamage accumulation in human compact bone. Bone. December 1995;17(6):521-525.
2001	Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone. August 2001;29(2):185-191.
1996	Wenzel TE, Schaffler MB, Fyhrie DP. In vivo trabecular microcracks in human vertebral bone. Bone. August 1996;19(2):89-95.
1996	Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. December 7, 1996;348(9041):1535-1541.
1998	Fazzalari NL, Forwood MR, Smith K, Manthey BA, Herreen P. Assessment of cancellous bone quality in severe osteoarthrosis: bone mineral density, mechanics, and microdamage. Bone. 1998;22(4):381-388.
1997	Norman TL, Wang Z. Microdamage of human cortical bone: incidence and morphology in long bones. Bone. April 1997;20(4):375-379.
1997	Burr DB, Forwood MR, Fyhrie DP, Martin RB, Schaffler MB, Turner CH. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res. January 1997;12(1):6-15.
1995	Burr DB, Hooser M. Alterations to the en bloc basic fuchsin staining protocol for the demonstration of microdamage produced in vivo. Bone. October 1995;17(4):431-433.
2001	Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tiss Int. November 2001;69(5):281-286.
1990	Burr DB, Stafford T. Validity of the bulk-staining technique to separate artifactual from in vivo bone microdamage. Clin Orthop Relat Res. November 1990;260:305-308.

Cited By (23)

Year	Entry
2008	Kennedy OD, Brennan O, Mauer P, Rackard SM, O'Brien FJ, Taylor D, Lee TC. The effects of increased intracortical remodeling on microcrack behaviour in compact bone. Bone. November 2008;43(5):889-893.
2009	Garrison JG, Slaboch CL, Niebur GL. Density and architecture have greater effects on the toughness of trabecular bone than damage. Bone. May 2009;44(5):924-929.
2011	Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone. July 2011;49(1):56-65.
2011	Tjhia CK, Odvina CV, Rao DS, Stover SM, Wang X, Fyhrie DP. Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone. December 2011;49(6):1279-1289.
2013	Ettinger B, Burr DB, Ritchie RO. Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone. August 2013;55(2):495-500.
2021	Jensen PR, Andersen TL, Chavassieux P, Roux J-P, Delaisse J-M. Bisphosphonates impair the onset of bone formation at remodeling sites. Bone. April 2021;145:115850.
2022	Ozasa R, Saito M, Ishimoto T, Matsugaki A, Matsumoto Y, Nakano T. Combination treatment with ibandronate and eldecalcitol prevents osteoporotic bone loss and deterioration of bone quality characterized by nano-arrangement of the collagen/apatite in an ovariectomized aged rat model. Bone. April 2022;157:116309.
2005	Seref-Ferlengez Z, Kennedy OD, Schaffler MB. Bone microdamage, remodeling and bone fragility: how much damage is too much damage? BoneKEy Rep. March 18, 2005;4:644.
2015	Seref-Ferlengez Z, Kennedy OD, Schaffler MB. Bone microdamage, remodeling and bone fragility: how much damage is too much damage? BoneKEy Rep. March 2015;4:644.
2011	Green JO, Wang J, Diab T, Vidakovic B, Guldberg RE. Age-related differences in the morphology of microdamage propagation in trabecular bone. J Biomech. October 13, 2011;44(15):2659-2666.
2007	Chapurlat RD, Arlot M, Burt‐Pichat B, Chavassieux P, Roux JP, Portero‐Muzy N, Delmas PD. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long‐term bisphosphonates: a bone biopsy study. J Bone Miner Res. October 2007;22(10):1502-1509.
2007	Allen MR, Burr DB. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res. November 2007;22(11):1759-1765.
2008	Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. January 2008;23(1):6-16.
2010	Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MCH, Weinstein RS, Whyte M. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. November 2010;25(11):2267-2294.
2012	Bala Y, Depalle B, Farlay D, Douillard T, Meille S, Follet H, Chapurlat R, Chevalier J, Boivin G. Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. J Bone Miner Res. April 2012;27(4):825-834.
2023	Pienkowski D, Wood CL, Malluche HH. Trabecular bone microcrack accumulation in patients treated with bisphosphonates for durations up to 16 years. J Orthop Res. May 2023;41(5):1033-1039.
2011	O'Neal JM. The Effects of Aging and Remodeling on Bone Quality and Microdamage [PhD thesis]. Atlanta, GA: Georgia Institute of Technology; August 2011.
2011	Garrison JG. The Relative Importance of Stress State, Microarchitecture, and Damage Burden in the Failure Behavior of Trabecular Bone [PhD thesis]. University of Notre Dame; April 2011.
2011	Ross RD. Functionalized Gold Nanoparticles as Damage-Specific X-Ray Computed Tomography Contrast Agents in Bone Tissue [PhD thesis]. University of Notre Dame; November 2011.
2009	Ruppel ME. Alterations in the Mineral and Collagen Matrix of Bisphosphonate-Treated Bone and Osteoblasts [PhD thesis]. Stony Brook, NY: Stony Brook University; May 2009.
2012	Kwaczala AT. Alendronate and PTH Differentially Modulate Bone Quality and Reduce Adiposity in an OVX Rat Model [PhD thesis]. Stony Brook, NY: Stony Brook University; December 2012.
2012	Tjhia CKH. Bone Quality of Patients With Atypical Fractures and Severely Suppressed Bone Turnover [PhD thesis]. Davis, University of California; 2012.
2019	Demirtas A. Assessment of the Influence of Possible Side Effects of Long-Term Bisphosphonate Treatment on Cortical Bone Fracture Resistance Using Finite Element Modeling [PhD thesis]. Villanova, PA: Villanova University; July 2019.